The comparison efficacy and safety of topical caspofungin ?.5% and topical voriconazole 1% in fungal keratitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231219060471N1

Enrollment

Registered

2024-02-16

Start date

2024-01-19

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

FUNGAL KERATITIS. Mycoses, Disorders of sclera, cornea, iris and ciliary body, Disorders of sclera and cornea in diseases classified elsewhere

Interventions

Intervention 1: Intervention group: For the treatment of fungal keratitis, topical caspofungin 0.5% will be administered. A vial of caspofungin 50 mg is to be diluted with 10.5 cc of Ringer Lactate, a

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Smear or culture positive fungal keratitis or fungal keratitis with negative smear or culture which is diagnosed by confocal scan Corneal ulcer with a 5mm maximum diameter, involving 4 mm of the center of the cornea, and extending less than 5?% of the corneal stromal depth

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The efficacy and safety of topical caspofungin 0.5% and topical voriconazole 1% will be compared in treating fungal keratitis. Clinical response, scar formation, corneal scar size, visual acuity outcomes, and size and depths of corneal infiltration will also be evaluated. Timepoint: An ophthalmic examination will be conducted daily during hospitalization, on the 7th, 14th, and 30th days, as well as on the 3rd month. Method of measurement: A clinical examination will be conducted by an expert ophthalmologist. The examination will involve the use of a slit-lamp biomicroscopy to detect clinical response and measure the size and depth of infiltration using a caliper. The size and depth of the corneal scar will also be detected with a slit lamp and measured using a caliper. All clinical responses will be recorded by slit-lamp photography in each examination.	—

Measure

Time frame

The efficacy and safety of topical caspofungin 0.5% and topical voriconazole 1% will be compared in treating fungal keratitis. Clinical response, scar formation, corneal scar size, visual acuity outcomes, and size and depths of corneal infiltration will also be evaluated. Timepoint: An ophthalmic examination will be conducted daily during hospitalization, on the 7th, 14th, and 30th days, as well as on the 3rd month. Method of measurement: A clinical examination will be conducted by an expert ophthalmologist. The examination will involve the use of a slit-lamp biomicroscopy to detect clinical response and measure the size and depth of infiltration using a caliper. The size and depth of the corneal scar will also be detected with a slit lamp and measured using a caliper. All clinical responses will be recorded by slit-lamp photography in each examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehran Zarei Ghanavati

Tehran University of Medical Sciences

m-zareigh@sina.tums.ac.ir+98 21 5542 1080

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026